

Date: 31-07-2017

To
Mr. BhushanMokashi
Manager
Bombay Stock Exchange Limited,
PhirozeJeeJeebhoy Towers,
Dalal Street, MUMBAI – 400 001.

Sir,

Sub: Outcome of the Board Meeting – Reg.

Ref: Our Company code no: 532041.

The following is the Outcome of the Board Meeting of the Company held on 31st July, 2017 at 02.00 P.M. at the registered office of the Company:

 The Board has approved the un-audited financial results of the company for the quarter ended on 30th June, 2017.

 The board has apporoved to be convend the 25th Annual General Meeting of the Company on 29th September 2017 at 10.00 A.M at the Registered Office of the Company.

We are herewith enclosing un-audited financial results of the company & Limited Review Report issued by the auditor for the quarter ended 30.06.2017, as per Regulation 33 (3) of SEBI (LODR) Regulations, 2015.

This is for your information and record.

Thanking you

Yours faithfully,

For Hindustan Bio Sciences Limited

J V R Mohan Raju Managing Director

Email: pharma.hindustanbio@gmail.com CIN: L26942TG1991PLC013564

HINDUSTAN BIO SCIENCES LIMITED

Plot No.31, Sagar Society, Road No.2, Banjara Hills, Hyderabad 500 034 Phone No. 23555161,Fax 40205171

STATEMENT OF UN AUDITED RESULTS FOR THE PERIOD ENDED 30th JUNE, 2017

Rs. In lakhs

SI. No.	Particulars	Quarter ended			Year ended 31.03.2017
		30.06.2017 31.03.2017 30.06.2016			
		(unaudited)	(Audited)	(unaudited)	(Audited)
1	Income from Operations				
	(a) Revenue from operations		30.25	- 97	101.2
	(b) Other Income		*		- 19
	Total Revenue (1)	1981	30.25	- 0.0	101.2
2	Expenses			1948	
1	(a) cost of material consumed				
	(b) Purchases of Stock -in-trade		18.50	150	72.7
	(c) Changes in Inventories of finished goods, Stock -				
	in-Trade and Work-in-Progress	690	-		
	(d) Employee Benefit Expenses	5.48	11.09	5.41	26.7
	(e) Finance Costs	0.10	0.01	0.70	- 1.
	(f) Selling Expenses	12	0.33	320	1.1
	(g) Depreciation and amortisation Expenses	0.23	0.30	0.25	1.0
	(h) Other Expenses	5.71	15.68	6.49	47.
	Total Expenses(2)	11.52	45.91	12.85	149.9
3	Profit/(Loss) before Exceptional& Extraordinary items and tax (1 -2)	(11.52)	(15.66)	(12.85)	(48.
	Exceptional items	100	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		
5	Profit/(Loss) before tax(3 -4)	(11.52)	(15.66)	(12.85)	(48.
	Tax Expenses	3000000		1,000,000	100000
	(a) Current Tax				
	(b) Deferred Tax		(0.41)	200	(0.4
7	Profit /(Loss) for the period from continuing operations(5-6)	(11.52)	(16.07)	(12.85)	(49.
	Profit /(Loss) from discontinued operations	(11.02)	(10.01)	(12.00)	(40.
	Tax Expense of discontinued operations	10		3.50	
	Profit /Loss from Discontinued operations after tax(8-9)		8	3.50	3.5
	Profit/(Loss) for the period(7+10)	(11.52)	(16.07)	(12.85)	(49.
	Other Comprehensive Income	(11.52)	(10.07)	(12.00)	(45.
12	A (1) Items that will not be reclassified to profit or loss	25	2	1121	003
	(2) Income tax relating to items that will not be re-				
	classified to profit or loss			•	
		18		(#S	
	B (1) Items that will be reclassified to profit or loss (2) Income tax relating to items that will be reclassified	- 8			
	to profit or loss			l leas	
-42	Total Comprehensive Income for the period (11+12)	(44.52)	440.071	(40.00)	
13		(11.52)	(16.07)	(12.85)	(49.
4.4	(comprising Profit (Loss) and other comprehensive income for the period) Paid up Equity Capital (Face Value Rs.10/- each)	4 025 00	4 005 00	4 005 00	4.005
	Reserves excluding Revaluation Reserves as per balance sheet of	1,025.08	1,025.08	1,025.08	1,025.
15	previous accounting year				/500
40	Earnings per equity share for continuing operations				(592.
10	(A) Basic	10.44	(0.40)	40.40	
	(B) Diluted	(0.11)			(0.
47	Earnings per equity share for discontinuing operations	(0.11)	(0.16)	(0.13)	- (0.
11	(A) Basic				
	(B) Diluted	- 51			100
40		7.5		015	500
10	Earnings per equity share(for discontinuing & continuing operations (A) Basic	70.44	10.45	40.40	
		(0.11)	1 0 0	100	77850
	(B) Diluted	(0.11)	(0.16)	(0.13)	(0.

Notes:

1 UnAudited Financial Results were taken on record by the Board of Directors in their meeting held on 31.07.2017

2 Previous year figures have been regrouped wherever necessary

J.V.R.Mohan Raju Managing Director

For Hindustan Bio Sciences Limited

Place: Hyderabad Date: 31.07.2017

VASG & ASSOCIATES

Chartered Accountants

503/A, 5th Floor, Kubera Towers, Narayanaguda, Hyderabad-500 029. Ph.: 040 - 6684 9660

Email: vasgassociates@gmail.com

Info@vasg-ca.com website: www.vasg-ca.com

Limited Review Report

Review Report to the Board of Directors Hindustan Bio Sciences Ltd.

We have reviewed the accompanying statement of unaudited financial results of M/s. Hindustan Bio Sciences Limited ('the Company') for the quarter ended June 30, 2017 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulations 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, read with SEBI Circular No.CIR/CFD/FAC/62/2016 date July 05, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditors of the Entity, issued by the institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We do no express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulations 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, read with SEBI Circular No.CIR/CFD/FAC/62/2016 date July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For VASG & ASSOCIATES

Chartered Accountants

Firm Reg No. 006070S

(A.Viswanatha Rao)

Partner

M.No:029597

Place: Hyderabad Date: 31.07.2017